Colorectal CancerEarlyCRCNCT06452745
Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
An observational study of Colorectal Cancer and Colorectal Adenoma, run by Institut Investigacio Sanitaria Pere Virgili at 2 sites in Spain.
Trial summary
Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with… Read more about this study
- Who is it for?
- Ages 50 to 70 years
- Conditions the study is for
- Colorectal Cancer, Colorectal Adenoma, Colorectal Polyp
- What is being tested?
- Colonoscopy and Urine and FOBT collection
- Type of treatment
- Surgery or procedure
- How many people
- 2,000 participants
- Where
- 2 sitesSpain
- Study dates
- 20 Jul 2019to 30 Jun 2040
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The cohort subject to the study are patients participating in the population screening program for colorectal cancer with a positive fecal occult blood test (FOBT) who are called to undergo a colonoscopy.
Who may be able to join
- Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.
Who cannot join
- Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer.
- Patients with severe kidney disease stage IV (creatinine clearance < 30 ml/min).
- Patients with severe active liver disease (hepatitis, cirrhosis).
- Refusal to sign informed consent.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Spain2 sites, 2 recruiting
- Recruiting
Hospital Universitari Sant Joan de Reus
Reus, Tarragona, 43204
Josep Gumà, PhD, +34977310300, josep.guma@salutsantjoan.cat
Josep Gumà, PhD
- Recruiting
Hospital Universitari Joan XXIII
Tarragona, Tarragona, 43005
Joan C Quer-Boniquet, PhD, +34977295800, jquer.hj23.ics@gencat.cat
Joan C Quer-Boniquet, MD
About this study
Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and/or radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent.
The purpose of the EarlyCRC project is to determine whether metabolites (substances of low molecular weight) can be found in the urine and stool of patients with colorectal cancer or polyps that can be easily and cheaply differentiated (urine or stool analysis) between the patients affected by colorectal cancer or polyps, from healthy individuals. For the identification of these possible metabolites, the urine analysis will be performed using the usual techniques in metabolomics, which studies the existing metabolites in biological processes.
Read the detailed description
Colorectal cancer (CRC) is the most frequent neoplasm in our environment if both sexes are considered together. It is the second most common neoplasm in women, after breast cancer, and the second most common in men after prostate cancer. In terms of mortality, CRC is the second leading cause of cancer death in men, after lung cancer, and second in women after breast cancer. For the year 2013, 735 cases and 262 deaths from colorectal cancer were estimated in the province of Tarragona. Since 1982, incidence rates have increased annually by more than 3% in men and by almost 2% in women. It is estimated that if no early diagnosis program was carried out, in 2020 about 900 new cases of CRC would be diagnosed, and about 300 deaths would occur1.
These figures vary according to one or other geographical areas of the world. If we consider the European population as a whole, colorectal cancer is the third most common tumor for both sexes together, after breast cancer and prostate cancer. It is the third most common tumor in men, after prostate cancer and lung cancer, and the second most common in women, after breast cancer. The mortality figures in Europe place colorectal cancer in third place for both sexes together, after lung and breast cancer, so that in men it is surpassed only by lung cancer and in women by breast cancer2 .
As in the vast majority of cancers, age is the main non-modifiable risk factor for colon and rectal cancer. More than 90% of cases are diagnosed in people over 50 years old. There is an increased risk of CRC in those with hereditary diseases such as familial colonic polyposis or Lynch syndrome, although the vast majority of colorectal cancers (more than 90% of cases) do not have a hereditary component. With respect to the modifiable risk factors, one of the most important is the consumption of red and processed meat, or meat that is heavily cooked or cooked in direct contact with fire. On the other hand, fiber, fruit and vegetable consumption, as well as dairy and micronutrients such as folate and calcium, are protective against this cancer. All these dietary factors affect the risk of the appearance of the precursor lesions of cancer, colorectal adenomas. Obesity is another risk factor, and exercise and physical activity act as protectors. Thus, CRC is considered to be caused by a combination of genetic and environmental factors, which lead to the appearance of adenomatous polyps as a premalignant lesion, and which over time acquire new mutations in their genetic material until become an adenocarcinoma1,3.
The early diagnosis of cancer and, more specifically, that of colorectal cancer, aims to detect colorectal tumors in the initial stages as well as premalignant lesions, colonic polyps. As with all neoplastic diseases, the stage at the time of diagnosis is the most important prognostic factor when it comes to survival. In this way, it has been shown that a test capable of easily and minimally invasively diagnosing the initial stages of colorectal cancer can reduce mortality from this tumor by 15-20% in program participants4. The fact of being able to detect benign polyps not only reduces mortality from colorectal cancer, but also decreases its incidence, since the removal of polyps prevents their subsequent malignancy. Currently, the test used in the early diagnosis of colorectal cancer is the determination of occult blood in faeces from the age of 50, every two years. In the event that the test comes out positive, the patient is subsequently subjected to a colonoscopic study. Collection of the faecal sample by itself may have low acceptance and therefore may compromise population participation in screening. A urine test, with an easier and "cleaner" collection technique, could be an added advantage in an early diagnosis program.
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Polyp, Healthy
- Being tested
- Colonoscopy, Urine and FOBT collection
- Keywords
- screening, urine, fobt, biomarkers, metabolomics
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ColonoscopyProcedure or surgery
Colonoscopy performed as a regular practice during colorectal cancer screening.
Urine and FOBT collectionOther
After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.
| Study group | Role | What they receive |
|---|---|---|
| Colorectal Cancer | Diagnosed colorectal cancer after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. Receives: Procedure: Colonoscopy; Other: Urine and FOBT collection | |
| Adenomatous high risk polyps | Diagnosed adenomatous high risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With = or > 10 adenomas or serrated polyps and/or any sessile or flat lesion of = or >20 mm (pediculated = or >20 mm are not high risk). Receives: Procedure: Colonoscopy; Other: Urine and FOBT collection | |
| Adenomatous medium risk polyps | Diagnosed adenomatous medium risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 5 to 9 non-advanced serrated adenomas or polyps and/or at least 1 advanced lesion (adenoma >10mm and/or hairy component and/or high-grade dysplasia or serrated polyp >10mm and/or dysplasia). Receives: Procedure: Colonoscopy; Other: Urine and FOBT collection | |
| Adenomatous low risk polyps | Diagnosed adenomatous low risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 1 to 4 non-advanced adenomas (<10mm, without hairy component or high-grade dysplasia) or non-advanced serrated polyps (<10mm, without dysplasia). Receives: Procedure: Colonoscopy; Other: Urine and FOBT collection | |
| Healthy | No luminal lesions are observed during the colonoscopy. Receives: Procedure: Colonoscopy; Other: Urine and FOBT collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Colonoscopy results
Histopathological analysis of biopsy and polypectomy pieces.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2024
- Study start20 Jul 2019
- Primary completion30 Jun 2030 (estimated)
- Study completion30 Jun 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Investigacio Sanitaria Pere Virgili
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Raquel Cumeras, Institut Investigacio Sanitaria Pere Virgili
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06452745
- Sponsor's protocol ID
- 114/2019
- Acronym
- EarlyCRC
- Status last verified
- Jun 2024
- First submitted
- 5 Jun 2024
- Last updated
- 2 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
- ClinicalTrials.gov ID
- NCT06452745
- Acronym / sponsor ID
- EarlyCRC / 114/2019
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Polyp, Healthy
- Keywords
- screening, urine, fobt, biomarkers, metabolomics
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Institut Investigacio Sanitaria Pere VirgiliUniversity, hospital or other
- Study start
- 20 Jul 2019 (actual)
- Primary completion
- 30 Jun 2030 (estimated)
- Study completion
- 30 Jun 2040 (estimated)
- First posted
- 11 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and/or radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent.
The purpose of the EarlyCRC project is to determine whether metabolites (substances of low molecular weight) can be found in the urine and stool of patients with colorectal cancer or polyps that can be easily and cheaply differentiated (urine or stool analysis) between the patients affected by colorectal cancer or polyps, from healthy individuals. For the identification of these possible metabolites, the urine analysis will be performed using the usual techniques in metabolomics, which studies the existing metabolites in biological processes.
Detailed description
Colorectal cancer (CRC) is the most frequent neoplasm in our environment if both sexes are considered together. It is the second most common neoplasm in women, after breast cancer, and the second most common in men after prostate cancer. In terms of mortality, CRC is the second leading cause of cancer death in men, after lung cancer, and second in women after breast cancer. For the year 2013, 735 cases and 262 deaths from colorectal cancer were estimated in the province of Tarragona. Since 1982, incidence rates have increased annually by more than 3% in men and by almost 2% in women. It is estimated that if no early diagnosis program was carried out, in 2020 about 900 new cases of CRC would be diagnosed, and about 300 deaths would occur1.
These figures vary according to one or other geographical areas of the world. If we consider the European population as a whole, colorectal cancer is the third most common tumor for both sexes together, after breast cancer and prostate cancer. It is the third most common tumor in men, after prostate cancer and lung cancer, and the second most common in women, after breast cancer. The mortality figures in Europe place colorectal cancer in third place for both sexes together, after lung and breast cancer, so that in men it is surpassed only by lung cancer and in women by breast cancer2 .
As in the vast majority of cancers, age is the main non-modifiable risk factor for colon and rectal cancer. More than 90% of cases are diagnosed in people over 50 years old. There is an increased risk of CRC in those with hereditary diseases such as familial colonic polyposis or Lynch syndrome, although the vast majority of colorectal cancers (more than 90% of cases) do not have a hereditary component. With respect to the modifiable risk factors, one of the most important is the consumption of red and processed meat, or meat that is heavily cooked or cooked in direct contact with fire. On the other hand, fiber, fruit and vegetable consumption, as well as dairy and micronutrients such as folate and calcium, are protective against this cancer. All these dietary factors affect the risk of the appearance of the precursor lesions of cancer, colorectal adenomas. Obesity is another risk factor, and exercise and physical activity act as protectors. Thus, CRC is considered to be caused by a combination of genetic and environmental factors, which lead to the appearance of adenomatous polyps as a premalignant lesion, and which over time acquire new mutations in their genetic material until become an adenocarcinoma1,3.
The early diagnosis of cancer and, more specifically, that of colorectal cancer, aims to detect colorectal tumors in the initial stages as well as premalignant lesions, colonic polyps. As with all neoplastic diseases, the stage at the time of diagnosis is the most important prognostic factor when it comes to survival. In this way, it has been shown that a test capable of easily and minimally invasively diagnosing the initial stages of colorectal cancer can reduce mortality from this tumor by 15-20% in program participants4. The fact of being able to detect benign polyps not only reduces mortality from colorectal cancer, but also decreases its incidence, since the removal of polyps prevents their subsequent malignancy. Currently, the test used in the early diagnosis of colorectal cancer is the determination of occult blood in faeces from the age of 50, every two years. In the event that the test comes out positive, the patient is subsequently subjected to a colonoscopic study. Collection of the faecal sample by itself may have low acceptance and therefore may compromise population participation in screening. A urine test, with an easier and "cleaner" collection technique, could be an added advantage in an early diagnosis program.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Colorectal Cancer | – | Procedure: Colonoscopy, Other: Urine and FOBT collectionDiagnosed colorectal cancer after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. |
| Adenomatous high risk polyps | – | Procedure: Colonoscopy, Other: Urine and FOBT collectionDiagnosed adenomatous high risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With = or > 10 adenomas or serrated polyps and/or any sessile or flat lesion of = or >20 mm (pediculated = or >20 mm are not high risk). |
| Adenomatous medium risk polyps | – | Procedure: Colonoscopy, Other: Urine and FOBT collectionDiagnosed adenomatous medium risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 5 to 9 non-advanced serrated adenomas or polyps and/or at least 1 advanced lesion (adenoma >10mm and/or hairy component and/or high-grade dysplasia or serrated polyp >10mm and/or dysplasia). |
| Adenomatous low risk polyps | – | Procedure: Colonoscopy, Other: Urine and FOBT collectionDiagnosed adenomatous low risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 1 to 4 non-advanced adenomas (<10mm, without hairy component or high-grade dysplasia) or non-advanced serrated polyps (<10mm, without dysplasia). |
| Healthy | – | Procedure: Colonoscopy, Other: Urine and FOBT collectionNo luminal lesions are observed during the colonoscopy. |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The cohort subject to the study are patients participating in the population screening program for colorectal cancer with a positive fecal occult blood test (FOBT) who are called to undergo a colonoscopy.
Key inclusion criteria (1 listed)
- Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.
Key exclusion criteria (4 listed)
- Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer.
- Patients with severe kidney disease stage IV (creatinine clearance < 30 ml/min).
- Patients with severe active liver disease (hepatitis, cirrhosis).
- Refusal to sign informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ColonoscopyColonoscopy performed as a regular practice during colorectal cancer screening. | Procedure or surgery | Adenomatous high risk polyps, Adenomatous low risk polyps, Adenomatous medium risk polyps, Colorectal Cancer, Healthy |
| Urine and FOBT collectionAfter patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon. | Other | Adenomatous high risk polyps, Adenomatous low risk polyps, Adenomatous medium risk polyps, Colorectal Cancer, Healthy |
Primary outcome
Colonoscopy results
Time frame: 3 months
Histopathological analysis of biopsy and polypectomy pieces.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2024.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer and Colorectal Adenoma, run by Institut Investigacio Sanitaria Pere Virgili at 2 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Colonoscopy results (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2024.